Back to Archived Journals » Advances in Genomics and Genetics » Volume 2

Mutational analysis of APOL1 in patients with Fechtner and Epstein syndromes: no evidence of a digenic etiology in MYH9-related disorders with renal disease

Authors McGredy M, Martignetti JA, Babcock

Received 12 April 2012

Accepted for publication 16 May 2012

Published 4 July 2012 Volume 2012:2 Pages 49—54


Review by Single anonymous peer review

Peer reviewer comments 2

Maxine McGredy,1 John A Martignetti,1–3 Melanie Babcock1

1Departments of Genetics and Genomic Sciences, 2Pediatrics, 3Oncological Sciences, Mount Sinai School of Medicine, New York, NY, USA

Abstract: Mutations in MYH9 result in a group of clinically overlapping autosomal dominant macrothrombocytopenia syndromes, collectively termed the MYH9-related disorders (MYH9RD). Intriguingly, three of these disorders, Fechtner, Alport-like, and Epstein syndromes, are associated with the additional clinical phenotype of glomerulosclerosis. Recently, an abundance of studies have demonstrated that the APOL1 gene, contiguous to MYH9, is associated with a form of kidney disease in individuals of African ancestry. Given these findings related to kidney disease arising in mutations in two contiguous genes, this study aimed to determine whether APOL1 mutations could also be present in patients with Fechtner (FTNS) and Epstein (EPS) syndromes. This study used sequence analysis to investigate a discrete discovery set of FTNS patients, but did not identify second hit mutations in APOL1.

Keywords: APOL1, MYH9, Fechtner syndrome, Epstein syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]